08:00 , Jan 2, 2012 |  BC Week In Review  |  Company News

Adagio Pharmaceuticals, Cynapsus deal

Cynapsus completed its acquisition of Adagio in a stock deal valued at C$520,000 ($509,340) based on Cynapsus' close of C$0.02 on Dec. 21, the day before the close was announced. Adagio shareholders will receive 26...
07:00 , May 2, 2011 |  BC Week In Review  |  Company News

Adagio Pharmaceuticals, Cynapsus deal

Cynapsus will acquire Adagio in a stock deal valued at C$1 million (US$1.1 million) based on Cynapsus' close of C$0.04 on April 26, before the acquisition was announced. Adagio shareholders will receive 26 million Cynapsus...
07:00 , Aug 2, 2010 |  BC Week In Review  |  Company News

Adagio Pharmaceuticals, Cynapsus deal

Adagio granted Cynapsus (formerly Cannasat Therapeutics Inc.) an exclusive option for exclusive, worldwide rights to develop and commercialize Adagio's APL-130277. The small molecule dopamine receptor agonist is an oral formulation of apomorphine to...
08:00 , Feb 15, 2010 |  BC Week In Review  |  Company News

Adagio Pharmaceuticals, Cannasat deal

The companies signed a letter of intent granting Cannasat an exclusive option to obtain exclusive, worldwide rights to develop and commercialize Adagio's APL-130277 to treat Parkinson's disease. Cannasat will have a 12-month option period...